[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nerve-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nerve-injury":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,76,103,127,159,193,217,249,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100612884","neuro-inflammation-in-extremity-trauma-risk-verification-in-elbow-trauma-the-nerve-study-100612884",false,"NCT07259382","Neuro-Inflammation in Extremity Trauma: Risk Verification in Elbow Trauma: The NERVE Study","Neuro-Inflammation in Extremity Trauma: Risk Verification in Elbow Trauma: The NERVE Pilot Cohort Study","NERVE","Inclusion Criteria:\n\n* Adults 18 years or older with an acute elbow fracture and\u002For dislocation less than a week old\n* Open surgery as the chosen treatment\n\nExclusion Criteria:\n\n* Patient with a history of ipsilateral upper limb trauma or pathology, neurological disorder.\n* Patient unable to answer questionnaires.\n* Patient unavailable for a one-year follow-up, for example from another country.\n* Patient with vascular injury or open fracture\n* Patient with an active inflammatory disease (ex: rheumatoid arthritis)\n* Patient using anti-inflammatory drugs or immunosuppressants at the time of the injury.\n* Patient with another acute ipsilateral injury to the upper limb\n* Polytrauma patients with other injuries than the elbow fracture and concomitant central or peripheral neurological injury.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","The primary goal of this proposal is to improve the understanding of the mechanisms causing persistent pain and disability in elbow fracture patients and their associated functional limitations. The specific objectives are as follows for elbow fractures:\n\n1\\) To describe NI mechanisms using biomarkers; 2) To identify factors related to increased NI biomarkers level; 3) To describe the associations between NI and outcomes; 4) To use these findings to refine a larger fully powered prognostic cohort study Hypotheses\n\n1. Level of neuro-inflammation (NI) biomarkers\\* will be significantly higher in patients presenting with both elbow fracture and CNS injury or PNI.\n2. Consumption of opioid in mg of morphine equivalent will be higher in patients with a higher level of NI biomarkers.\n3. Function, assessed by validated joint and limb specific functional questionnaires and QoL will be worse in patients with a higher level of NI biomarkers.\n4. Chronic pain at 3 months will be higher (McGill Pain questionnaire V2, Neuropathic pain questionnaire, NPRS) in patients with a higher level of NI biomarkers.\n5. Duration of tourniquet use and nerve dissection will be correlated to elbow fracture outcome with a higher level of NI biomarkers.\n\n   * Target biomarkers based on preliminary study will include, but not be limited to: TNFa, IL6, Substance P, IL-1B, TREM-2, IL-16, CCL22, VEGF-a, BMPs (table 1).",[25,26,27,28,29],"Elbow Dislocation","Elbow Fractures","Inflammation Biomarkers","TBI Traumatic Brain Injury","Nerve Injury",[31,32,33,34,35],"Biomarkers","Elbow fracture","elbow dislocation","Nerve injury","TBI","NOT_YET_RECRUITING","2026-04-27",{"date":39,"type":40},"2026-04-28","ACTUAL",{"date":42,"type":21},"2026-06-01",{"date":44,"type":21},"2030-12-31",{"name":46,"class":47},"Université de Montréal","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100467324","association-between-radial-artery-intervention-and-development-of-neuropathy-in-the-hand---a-prospective-study-100467324","NCT05365282","Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study","Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study - The ACCESS IV Study","ACCESS-IV","Inclusion Criteria:\n\n* The patient must be able to give informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Negative Barbeau test",{"count":57,"type":21},400,"Evaluation of potential nerve damage after radial CAG\u002FPCI.",[60,29,61],"Ischemic Heart Disease","Carpal Tunnel Syndrome",[63,60,64],"Transradial access","Hand Dysfunction","RECRUITING","2026-04-22",{"date":68,"type":40},"2026-04-23",{"date":70,"type":40},"2024-01-01",{"date":72,"type":21},"2028-12-01",{"name":74,"class":47},"Aarhus University Hospital Skejby",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100494675","regeneration-of-acutely-injured-nerves-with-temporary-electrical-stimulation-100494675","NCT05721261","Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation","REGAIN","Inclusion criteria:\n\n* Peripheral nerve injury\n\nExclusion criteria:\n\n* Peripheral neuropathy\n* Patients with any active implanted device",true,"65 Years",{"count":86,"type":21},110,"INTERVENTIONAL",[89],"NA","A novel temporary peripheral nerve stimulation system that delivers a single dose of electrical stimulation therapy for 1 hour will be evaluated for safety and effectiveness.",[29],"2026-03-12",{"date":94,"type":40},"2026-03-16",{"date":96,"type":40},"2023-08-11",{"date":98,"type":21},"2026-09",{"name":100,"class":101},"Epineuron Technologies Inc.","INDUSTRY",15,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":87,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":75},"100599416","a-study-to-expand-the-use-of-symani-surgical-system-for-peripheral-nerve-repair-100599416","NCT07084207","A Study to Expand the Use of Symani® Surgical System for Peripheral Nerve Repair","REGEN: A Prospective, Randomized, Open Label Study to Expand the Use of Symani® Surgical System for Peripheral Nerve Repair","REGEN","Pre-Operative\n\nInclusion Criteria:\n\n1. Adults, at the time of nerve injury aged from 18 to 70 years\n2. Patient agrees to participate in the study, returns for all required follow-up visits, and has willingly provided written informed consent after receiving all information related to the study and its requirements\n3. Complete loss of a nerve-specific receptive field of the finger\n4. Patient with a clinical indication for a microsurgical nerve coaptation in nerve injury that can be repaired by end-to-end suturing\n5. Patient with traumatic transection of one or more digit nerves distal to the carpal tunnel with sensory autonomous innervation areas on the finger or thumb tips\n6. Investigator considers candidate acceptable for either conventional epineural suturing or robotic-assisted epineural suturing\n7. The injury was treated within 10 days\n\nExclusion Criteria:\n\n1. Patients who are not capable and\u002For unwilling to provide informed consent\n2. Clinically significant cardiovascular, digestive, respiratory, endocrine, liver or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators' discretion.\n3. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes\n4. Patients belonging to vulnerable populations, such as pregnant women, or patients ineligible to participate for other reasons in the judgement of the investigator\n5. Indication for bilateral nerve repair\n6. Known impaired sensibility of the injured finger\n7. Patients with implanted pacemaker\n8. Replantation which includes bones\n\nIntra-Operative Inclusion Criteria\n\nIndividuals will be included in the study if the following criteria are met intraoperatively:\n\n1\\. Verification of a sensory nerve lesion without a gap and presence of a nerve that could be sutured in end-to-end fashion Intra-Operative Exclusion Criteria\n\nIndividuals will be excluded from participating in this study if any of the following criteria are met intraoperatively:\n\n1\\. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would","70 Years",{"count":113,"type":21},100,[89],"The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical nerve coaptation, following nerve injuries to the hand.\n\nThis study will include participants with traumatic sensory nerve lesions of a finger nerve distal to the carpal tunnel who are treated with nerve suturing.\n\nThe primary effectiveness endpoint is the two-point discrimination (2PD) test, at 6-months post index procedure.\n\nThe primary safety endpoint is the intraoperative serious adverse event rate.",[29,117],"Peripheral Nerve Injuries","2026-01-30",{"date":120,"type":40},"2026-02-03",{"date":122,"type":40},"2025-12-18",{"date":124,"type":21},"2027-12-18",{"name":126,"class":101},"MMI (Medical Microinstruments, Inc.)",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":87,"phases":137,"briefSummary":138,"conditions":139,"keywords":144,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100582736","evaluating-therapeutic-electrical-stimulation-to-improve-nerve-healing-after-surgical-repair-of-digital-nerve-injuries-100582736","NCT06867185","Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries","Function And Speed of Transection Recovery After Therapeutic Electrostimulation of Nerves","FASTR-TEN","Inclusion Criteria:\n\n* Age 18-80 years\n* Candidate for surgical intervention under general anesthesia.\n* Require primary nerve injury repair in at least 1 digital nerve.\n* Following resection, have a resulting nerve gap of ≤ 10mm.\n* Able to complete tension-free end-to-end direct repair, or repair with a conduit, autograft, or allograft with a length ≤15mm\n* Signed and dated informed consent form.\n\nExclusion Criteria:\n\n* Severe comorbid conditions, such as arrhythmia or congestive heart failure, preventing surgery under general anesthesia.\n* Nerve repair occurring \\>1 month post-injury.\n* Incomplete nerve transection.\n* Injury requiring replantation of target digit\n* Injury distal to the distal interphalangeal joint.\n* Injury proximal to branching into the proper or common digital nerves.\n* Injuries to both digital arteries of an affected digit.\n* History of neuropathy, diabetic neuropathy, or any other known neuropathy\n* History of chronic ischemic condition of the upper extremity\n* Cognitive impairment preventing the ability to provide consent, follow post-operative instructions, or complete clinical assessments.","80 Years",{"count":20,"type":21},[89],"The goal of this clinical study is to evaluate if a period of electrical stimulation delivered during the surgical repair procedure can speed up nerve healing.",[140,29,141,142,143],"Digital Nerve Injury","Nerve Reconstruction","Nerve Trauma","Digital Nerve Lesion",[145,146,147,148],"Nerve Repair","Therapeutic Electrical Stimulation","BES","Brief Electrical Stimulation","2026-01-08",{"date":151,"type":40},"2026-01-09",{"date":153,"type":40},"2025-04-24",{"date":155,"type":21},"2027-03",{"name":157,"class":101},"Checkpoint Surgical Inc.",5,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":166,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":87,"phases":171,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100339597","phase-2-4-aminopyridine-treatment-for-nerve-injury-100339597","NCT03701581","4-aminopyridine Treatment for Nerve Injury","4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy","Inclusion Criteria\n\n* Male patients with organ-confined, non-metastatic prostate cancer (stages cT1c-T2c), planning to undergo Robotic-Assisted Laparoscopic Bilateral Nerve Sparing Radical Prostatectomy (NSRP)\n* Prostate-Specific Antigen (PSA) levels less than 15 ng\u002Fml (within the last 12 months), with biopsy-proven prostate cancer, for whom postoperative adjuvant therapy (e.g. radiation or androgen deprivation therapy) is not expected to be needed\n* Ages 45-75\n* An Abridged International Index of Erectile Function-Erectile Function (IIEF-5) score of greater than or equal to 17 at time of screening\n* Has experienced at least 6 months of regular sexual activity and sexual activity during the 12 weeks prior to prostate biopsy or surgery\n* Willingness to abstain from treatments for Erectile Dysfunction until 3 months after surgery\n* Willingness to participate and able to provide informed consent\n\nExclusion Criteria\n\n* Planned adjuvant therapy after NSRP based on specimen pathology and stage of prostate cancer (stage T3 or greater), positive lymph nodes or positive surgical margins\n* Neo-adjuvant therapy prior to NSRP\n* History of recurrent prostate cancer\n* History of seizures, multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of non-organ confined or metastatic prostate cancer (clinical Stages T3 or greater)\n* History of known hypersensitivity to 4AP\n* Patients with history of penile surgery other than circumcision or endoscopic urethral stricture surgery\n* Renal impairment based on calculated GFR (GFR\\\u003C60 mL\u002Fmin)\n* Use of any other aminopyridine medications for any other indication","MALE","45 Years","75 Years",{"count":170,"type":21},70,[172,173],"PHASE2","PHASE3","To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and\u002For crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and\u002For crush injuries.",[29,176],"Prostate Cancer",[178,179,180,181,182],"prostatectomy","erectile dysfunction","prostate cancer","nerve injury","incontinence","2025-12-15",{"date":185,"type":40},"2025-12-17",{"date":187,"type":40},"2021-06-05",{"date":189,"type":21},"2028-12",{"name":191,"class":47},"John Elfar",2,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":87,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":75},"100598661","assessing-spinal-accessory-nerve-recovery-after-post-operative-electrical-stimulation-100598661","NCT07074392","Assessing Spinal Accessory Nerve Recovery After Post-operative Electrical Stimulation","Assessing the Feasibility and Effect of Post-operative Electrical Stimulation on Spinal Accessory Nerve Recovery After Neck Dissection for Head and Neck Cancer","SpARES","Inclusion Criteria:\n\n* Undergoing neck dissection\n\nExclusion Criteria:\n\n* Previous neck dissection, previous implantable stimulator (i.e. pacemaker), previous spinal accessory nerve injury, pre-existing shoulder injury or weakness",{"count":202,"type":21},38,[89],"Shoulder weakness and pain are common after neck dissection surgery for head and neck cancer. This is often caused by injury to the spinal accessory nerve, which controls important shoulder muscles. Recovery can be slow and incomplete, affecting patients' ability to return to daily activities. This project will test whether a brief, low-dose electrical stimulation treatment can help the nerve heal faster and improve shoulder function. The treatment is applied during surgery and is safe, non-invasive, and quick to deliver. If successful, this approach could lead to better rehabilitation, less disability, and improved quality of life for patients undergoing cancer surgery. The project also supports the development of new medical technology and offers a pathway to expand the use of electrical stimulation in other nerve injuries.",[206,29,207],"Head and Neck Cancer","Neck Dissection","2025-08-14",{"date":210,"type":40},"2025-08-19",{"date":212,"type":21},"2026-01-01",{"date":214,"type":21},"2027-03-01",{"name":216,"class":47},"McMaster University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":224,"maxAge":135,"enrollmentInfo":225,"targetDuration":4,"studyType":87,"phases":227,"briefSummary":228,"conditions":229,"keywords":238,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":75},"100373633","closed-loop-deep-brain-stimulation-for-refractory-chronic-pain-100373633","NCT04144972","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain Using Summit RC+S","Inclusion Criteria:\n\n1. Age 22-80 years old\n2. Clinical diagnosis of a refractory chronic pain syndrome including\n\n   1. post-traumatic pain syndromes (e.g. root avulsions, nerve crush injuries, spinal cord injury)\n   2. postsurgical pain syndromes (e.g., postmastectomy syndrome, post-thoracotomy syndrome, phantom limb pain, post-surgical spinal pain)\n   3. postherpetic neuralgia\n   4. complex regional pain syndrome\n   5. atypical facial pain\n   6. central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)\n   7. post-radiation plexopathy\n3. Two or more years or more of medically refractory severe pain\n4. Average daily pain for the past 30 days reported as \\>6 on a 0-10 numeric rating scale (NRS)\n5. Pain that fluctuates over a range of at least 3 points on the NRS\n6. Patient has failed at least two pain medications from different classes as determined by a neurologist or pain management specialist with stable doses of medications for 30 days prior to baseline visit.\n7. Lack of a surgically correctible etiology for the pain as determined by 2 independent surgeons\n8. Ability to speak \u002F read English\n9. Capable of understanding and providing informed consent\n10. Absence of significant cognitive impairment - score of 25 or greater on the Montreal Cognitive Assessment (MoCA)\n11. Successful detection of pain biomarkers or positive symptomatic response to inpatient stimulation trial period if performed.\n\nExclusion Criteria:\n\n1. Major medical co-morbidities increasing the risk of surgery including uncontrolled hypertension, coagulopathy, severe diabetes, major organ system failure, active infection or history of implant related infections, immunocompromised state or malignancy with \\\u003C 5 years life expectancy\n2. Presence of cardiac pacemakers\u002Fdefibrillators, implanted medication pumps, intra-cardiac lines, any intracranial implants (e.g., aneurysm clip, shunt, cochlear implant, electrodes) or other implanted stimulators not compatible with RC+S system\n3. Pregnancy or breast feeding: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.\n4. Active depression (BDI \\> 20), Suicide attempt \\\u003C\u002F= 12 months or imminent suicide risk, or other untreated or uncontrolled psychiatric illness that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation.\n5. History of substance abuse in past 3 years\n6. Inability to stop anticoagulation or platelet anti-aggregation therapy for surgery and recovery.\n7. Implantable hardware not compatible with MRI or with the study.\n8. MR abnormalities that suggest an alternative diagnosis or contraindicate surgery\n9. Previous cranial ablative surgery.\n10. Previous deep brain stimulation surgery using an RC+S incompatible system\n11. Major neurological disorder other than the one that led to the chronic pain including epilepsy or a neurodegenerative condition including inability to recharge the device.\n12. Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)\n13. Allergies or known hypersensitivity to materials in the Summit RC+S system\n14. Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS.","22 Years",{"count":226,"type":21},12,[89],"Chronic pain affects 1 in 4 US adults, and many cases are resistant to almost any treatment. Deep brain stimulation (DBS) holds promise as a new option for patients suffering from treatment-resistant chronic pain, but traditional approaches target only brain regions involved in one aspect of the pain experience and provide continuous 24\u002F7 brain stimulation which may lose effect over time. By developing new technology that targets multiple, complimentary brain regions in an adaptive fashion, the investigators will test a new therapy for chronic pain that has potential for better, more enduring analgesia.",[230,29,231,232,233,234,235,236,237],"Spinal Cord Injuries","Pain, Postoperative","Post Herpetic Neuralgia","Complex Regional Pain Syndromes","Post-Stroke Pain","Post Radiation Brain Injury","Post Radiation Plexopathy","Nerve Root Avulsion",[239],"Chronic Pain","2025-07-02",{"date":242,"type":40},"2025-07-08",{"date":244,"type":40},"2019-10-24",{"date":246,"type":21},"2030-10-24",{"name":248,"class":47},"University of California, San Francisco",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":87,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":75},"100566970","phase-2-a-study-of-bevonescein-in-patients-undergoing-abdominopelvic-surgery-100566970","NCT06662097","A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery","Multicenter Open-Label Feasibility Study of Intraoperative Nerve and Ureter Visualization With Bevonescein in Patients Undergoing Minimally Invasive Abdominopelvic Surgery","Inclusion Criteria:\n\n* Must be a minimum of 18 years of age\n* Study participant is planning to proceed with surgery\n* Willing to provide informed consent\n* Sexually active patients must be willing to use an acceptable form of contraceptive while participating and 30 days after.\n* Females of childbearing potential must have a negative pregnancy test at screening and during the study.\n\nExclusion Criteria:\n\n* Patient has had prior surgery at the intended surgical site.\n* Patient has abnormal cardiac rhythm not controlled by medication.\n* Patient has moderate to severe renal impairment.\n* Patient has a history of fluorescein allergy.\n* Patient has a history of drug-related anaphylactic.\n* Presence of a concurrent disease or condition that may interfere with study participation.\n* Presence or history of any condition that, in the view of the investigator, places the patient at high risk of treatment compliance.\n* Use of any Investigational Product or investigational medial device within 30 days prior to screening.",{"count":257,"type":21},64,[172],"Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery",[261,29,262],"Surgery","Imaging","2024-10-25",{"date":265,"type":40},"2024-10-28",{"date":267,"type":40},"2024-10-16",{"date":269,"type":21},"2025-09",{"name":271,"class":101},"Alume Biosciences, Inc.",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":279,"targetDuration":4,"studyType":87,"phases":280,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":75},"100507187","promoting-healing-of-injured-nerves-with-electrical-stimulation-therapy-100507187","NCT05884125","Promoting Healing of Injured Nerves With Electrical Stimulation Therapy","PHINEST","Inclusion Criteria:\n\n* Upper extremity mixed or motor nerve injury from the brachial plexus to the wrist crease.\n* Candidate for surgical intervention.\n* Indicated for surgical repair by nerve transfer, primary repair, or nerve grafting.\n* Are age 18-80 years.\n* Signed and dated informed consent form.\n\nExclusion Criteria:\n\n* Severe comorbid condition, such as arrhythmia or congestive heart failure, preventing surgery.\n* Primary repair requiring graft \\>6cm.\n* Nerve reconstruction occurring \\>12 months post injury.\n* Age less than 18 or greater than 80 years.\n* All contraindications to included\u002Frequired surgical procedure, including but not limited to language barriers, mental status barriers, inability to consent, and pregnancy\u002Flactation.",{"count":20,"type":21},[89],"This study is evaluating a new therapeutic use of electrical stimulation to promote nerve healing and improve functional recovery following surgical intervention for peripheral nerve injury in arm. Participants will be randomized into one of two groups, treatment or control, with all participants receiving standard of care treatment for the nerve injury. The treatment group will also receive a single dose of the therapeutic stimulation during the surgical intervention for their nerve injury.",[29,117,283,284],"Peripheral Nerve Injury Upper Limb","Nerve Palsy",[146,148,286,29,287,145],"Nerve Regeneration","Nerve Healing","2024-08-20",{"date":290,"type":40},"2024-08-21",{"date":292,"type":40},"2023-06-12",{"date":294,"type":21},"2027-06",{"name":157,"class":101}]